Call for Late Breaking Abstracts

The organizers of the 26th International Congress of The Transplantation Society
welcome the submission of late breaking abstracts for original contribution to the field.
Late Breaking Abstract Deadline: April 1, 2016 23:59 Eastern Standard Time

They will be accepted only for poster format and will not be published on the Transplantation Journal.
Please read the guidelines below. We encourage you to start the abstract submission early on. The system allows submitters to save their data and to make the final submission at a later date once all details have been completed.

User Profile

Before submitting an abstract, the submitter must create a User Profile. After an abstract has been created, modifications can be made until the submission deadline.

The final deadline to submit the late breaking abstract is April 1, 2016. Abstracts received after this date cannot be accepted. The submitting author will receive notification of acceptance by May 6, 2016. Together with the confirmation of acceptance of your abstract, presenters will be requested to register for the congress. Deadline for presenter registration is May 16, 2016.

Abstract Structure

Abstracts in all tracks should be structured chronologically in five sections: first Introduction; then Materials and Methods, Results, and Discussion (together, these three sections make up the paper's body); and finally, Conclusion.

  • The Introduction section clarifies the motivation for the work presented and prepares readers for the structure of the paper.
  • The Materials and Methods section provides sufficient detail for other scientists to reproduce the experiments presented in the paper. In some journals, this information is placed in an appendix, because it is not what most readers want to know first.
  • The Results and Discussion sections present and discuss the research results, respectively. They are often usefully combined into one section, however, because readers can seldom make sense of results alone without accompanying interpretation — they need to be told what the results mean.
  • The Conclusion section presents the outcome of the work by interpreting the findings at a higher level of abstraction than the Discussion and by relating these findings to the motivation stated in the Introduction. Explain the significance of your findings / outcomes and future implications of the results.

Important Dates

February 29, 2016 Late Breaking Abstract Opens
April 1, 2016 Late Breaking Abstract Deadline
April 15, 2016 Communication to Authors on Approved / Rejected Abstracts
May 6, 2016 Late Breaking Abstract Notification
May 16, 2016 Deadline for Presenter Registration (Early-Bird)
July 11, 2016 Detailed Program Online

Choosing a Track Category

During the submission process, you will be asked to select one track category for your abstract. The track category is the general heading under which the abstract will be reviewed and later published in the congress materials, if accepted. The track category which best describes the subject of the abstract should be chosen first, then you will be asked to select a sub-track (specialized category) and thirdly to identify which individual topic your abstract should be listed under. Refer to the track categories, sub-tracks and topics.

Basic and Translational Sciences Antigen Presentation and Allorecognition
  • All Topics
Immunosuppression Preclinical Studies
  • All Topics
Ischemia Reperfusion
  • All Topics
  • Basic Science of Rejection and Tolerance
  • B-Cell and Antibody
  • Innate Immunity, Chemokines, Cytokines and Complement
  • All Topics
  • Biomarkers, Bioinformatics, Immune Monitoring and Outcomes
  • Genomics and Other “omics”
  • Proteomics
Regeneration and Stem Cell Therapy
  • All Topics
T Lymphocyte Biology
  • Signalling, Metabolism, Regulation, Co-Stimulation
  • Sensitization and Memory
  • All Topics
Cell Transplantation Bone Marrow/HSC
  • Hemopoetic Stem Cell
  • Bone Marrow
Cell Transplantation
  • Stem Cell
  • Cellular Therapies
Regenerative Medicine
  • All Topics
Complications Complications - Cardiovascular
  • Kidney
  • Cardiovascular
Complications - Malignancy
  • Malignancy - All Topics
  • PTLD: all topics exept liver cancer recurrence
Complications - Metabolic
  • Metabolic
Composite Tissue Composite Tissue
  • Novel Vascularized Grafts
  • Vascularized Composite Allograft
Declaration of Istanbul Declaration of Istanbul  
Donation and Procurement Deceased Donation
  • Critical Care Management
  • Organ Donation
  • Public Policy
  • Regulation
Living Donors
  • Living Organ Donation
  • Organ Procurement and Preservation
Ethics, Community and Economics Ethics, Community and Economics
  • Economics and Administration
  • Ethical Issues
  • Health Economics
  • Quality of Life and Psychosocial
  • Social Media
Gender in Transplantation Gender in Transplantation
  • Gender Issues in Transplantation
  • Women in Transplantation
Heart Heart  
Histocompatibility Histocompatibility
  • Histocompatibility and Immunogenetics
Infectious Diseases Infectious Diseases
  • All Topics
Intestine and Multivisceral Intestine and Multivisceral  
Kidney ABO Incompatible
  • ABO Incompatible
Access and Allocation
  • Ageing and Kidney Transplantation
  • Kidney Access and Allocation
  • Pre-Transplant Management
  • Recipient Selection
Acute Injury
  • Acute Kidney Injury
  • Kidney Acute Cellular Rejection
Antibody Mediated Injury
  • Kidney Antibody Mediated Injury
  • Kidney Antibody Mediated Rejection
BKV Polyoma
  • Polyoma
Chronic Allograft Injury
  • Chronic Allograft Injury
DCD/ECD/SCD Transplants
  • Deceased Donor Issues
  • Extracorporeal Therapy
  • Kidney Immunosuppression Desensitization
Living Donor Transplant
  • Living Donor Transplant
  • Kidney Histopathology
  • Immunopathology
  • Recurrent Disease
Kidney Immunosuppression Clinical Tolerance
  • Clinical Studies
General Kidney Immunosuppression
  • Induction Therapy
  • General
Novel Agents
  • All Topics
  • Avoidance Protocols
  • Kidney Immunosuppression
  • Minimization
  • Optimization
Kidney Immunosuppression - Personalized Immunosuppression
  • Personalized Immunosuppression
  • Pharmacogenomics
  • Pharmacokinetics
Liver Allocation
  • Access and Allocation
  • Liver MELD and Donor Issues
Liver - Anesthesia and Critical Care
  • Anesthesia and Post-Op Critical Care
Immunosuppression and Tolerance
  • Immunosuppression, Minimization, Avoidance Protocols
  • Liver Immunosuppression
  • Liver Tolerance
Liver Malignancy
  • Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies
  • Combined Liver Kidney Issues
  • Liver Living Donor and Partial Grafts
  • Acute Rejection/Liver Chronic Allograft Injury
  • Complications
  • Recurrent Disease and Retransplantation
Recipient Selection and Management
  • All Topics
Liver Viral Hepatitis
  • All Topics
Lung Lung
  • All Topics
Paediatrics Paediatrics
  • Kidney Paediatrics
  • Liver Paediatrics
  • Other Paediatrics
Pancreas and Islet Islet
  • Islet Cell Transplantation
  • Pancreas Issues
Registries and Statistical Techniques Registries and Statistical Techniques
  • All Topics
Surgical Techniques Surgical Techniques
  • New Surgical Techniques (Video)
  • Transplant Anaesthesia
  • Transplant Critical Care
Transplantation in Developing Countries Transplantation in Developing Countries
  • Cultural and Ethnic Barriers
  • Developing Country Transplantation Issues
Transplantation Nursing Transplantation Nursing
  • All Other Topics
  • Treatment Non-Adherence
Xenotransplantation Xenotransplantation
  • All Topics

All abstracts must be submitted electronically through the Congress website

  • Abstracts will be accepted in English only
  • There is no fee for submitting an abstract
  • There are no limitations on the number of abstracts that an individual can submit. However, one individual can only present 2 abstract as oral presentations during the entire Congress. If you have more than 2 orals accepted, you will be obliged to identify alternate presenters for any abstract above the first two.
  • The abstract text body is limited to 3,000 characters (Approx 500 words) including spaces. A maximum of two figures (in JPG, GIF or PNG with ideally 600 dpi) can be included. These will not count toward the word limit, nor will the information about authors, institutions and study groups. File size of 2 MB maximum for each figure.
  • Abstracts accepted for oral or poster presentation will be published online in a supplement to the Transplantation Journal. Abstracts not accepted for presentation will not be published. Abstracts will also be posted prior to the meeting on the Congress website
  • Employees of Commercial Interests: TTS recognizes that employees of commercial interests are often involved in research and discovery and encourages these employees to submit abstracts to facilitate the flow of new information. Employees of commercial interests should submit abstracts when the content is limited to basic science research (e.g., pre-clinical research, drug discovery) or the processes/methodologies of research, themselves unrelated to a specific disease or compound/drug, and the abstract is not related to clinical applications of the research/discovery or clinical recommendations concerning the business lines or products of their employer.
  • Abstracts from employees of commercial interests that are selected for oral or poster presentation will be subject to an additional rigorous review to guard against presentation of content that is related to clinical recommendations concerning the business lines or products of the employer
  • Ensure that all co-authors approve of the abstract submission, publication, and potential presentation. Abstracts cannot be changed or withdrawn after February 5, 2016
  • Disclosure: abstract submitter and presenter are required to disclose any conflict of interest.
  • To be eligible to submit and abstract, you must disclose that the authors/ scientists have not violated any aspect of the Declaration of Istanbul (DOI) ethics' statement and that this research conforms with the ethical statements noted.
  • Presenter must confirm and register to the Congress by May 16, 2016, otherwise the abstract will not be published.

Copyright Policy

Abstracts should not include libelous or defamatory content. Material presented in abstracts should not violate any copyright laws. If figures/graphics/images have been taken from sources not copyrighted by the author, it is the author’s sole responsibility to secure the rights from the copyright holder in writing to reproduce those figures/graphics/images for both worldwide print and web publication. All reproduction costs charged by the copyright holder must be borne by the author.

Resubmission Policy

An abstract that has been previously published can only be submitted provided that there are new methods, findings, updated information or other valid reasons for submitting.


TTS regards plagiarism as serious professional misconduct. All abstracts are screened for plagiarism and when identified, the abstract and any other abstracts submitted by the same author will be rejected. In addition, the submitting author’s profile and scholarship application, in the case one has been submitted, will also be cancelled.

Ethics Compliance

To be eligible to submit and abstract, you must disclose that the author(s)/ scientist(s) comply with and have not violated:

Please note that no abstracts will be accepted which report transplants in which organs from executed people have been used.

Abstract Review

  • All submitted abstracts will go through blinded peer-review carried out by an international review committee.
  • All abstracts will be reviewed (blinded) by at least three international referees, selected by the organizing committee.
  • Abstracts which do not meet the focus of the topic category as requested by the authors will be reassigned to other category.
  • Scores assigned by all reviewers are averaged. The cut-off average score for acceptance is based on available oral and poster presentations. Rejections are further evaluated by the scientific program committee.
  • Poster and oral presentations are viewed as equally important components of the TTS Congress. Abstracts assigned to an oral presentation should stimulate discussion. The audience should also benefit from questions and answers following the presentation.

Rule of Two

Each presenting author may present a maximum of two abstracts as orals at the congress. The number of submissions is however not limited. Should an author have more than two abstracts accepted for presentation, a co-author must be named as presenting author for one or more abstracts.

Format of presentation

  • You may opt to submit your abstract to be considered for an oral presentation, an e-poster presentation, or either (at the committee’s discretion).
  • If your abstract is accepted as an “e-poster”, it can be assigned to either a standard e-poster or an e-poster with a short scheduled presentation.
  • If your abstract is accepted as an “oral”, it can be assigned to a full oral presentation, a shorter mini-oral or an interactive oral discussion.

Notification of Acceptance or Rejection to Corresponding Author

Notification of acceptance or rejection will be sent to the submitting (corresponding) author by April 15, 2016. Please note that only the corresponding author will receive mail concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract.

Premier Sponsor

astellas Transplant-NEW